Pieter Wesseling

Author PubWeight™ 140.42‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009 25.96
2 Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 2011 3.66
3 International Society Of Neuropathology--Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol 2014 3.21
4 IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res 2010 3.13
5 Germline mutation of INI1/SMARCB1 in familial schwannomatosis. Am J Hum Genet 2007 2.53
6 The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology 2013 2.14
7 Diffuse glioma growth: a guerilla war. Acta Neuropathol 2007 2.11
8 MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas. Lab Invest 2007 2.06
9 In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma. Cancer Cell 2010 1.94
10 Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option. Clin Cancer Res 2004 1.87
11 Receptor conversion in distant breast cancer metastases. Breast Cancer Res 2010 1.85
12 Heparan sulphate proteoglycans in Alzheimer's disease and amyloid-related disorders. Lancet Neurol 2003 1.84
13 Prognostic significance and mechanism of Treg infiltration in human brain tumors. J Neuroimmunol 2010 1.70
14 Activating mutations of the GNAQ gene: a frequent event in primary melanocytic neoplasms of the central nervous system. Acta Neuropathol 2010 1.65
15 CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo. Int J Cancer 2007 1.64
16 Vascular endothelial growth factor-A(165) induces progression of melanoma brain metastases without induction of sprouting angiogenesis. Cancer Res 2002 1.47
17 RAS/RAF pathway activation in gliomas: the result of copy number gains rather than activating mutations. Acta Neuropathol 2007 1.43
18 A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Clin Cancer Res 2011 1.40
19 Molecular diagnostics of gliomas: state of the art. Acta Neuropathol 2010 1.40
20 Successful treatment of Fusarium keratitis with cornea transplantation and topical and systemic voriconazole. Clin Infect Dis 2005 1.36
21 Development of a decision support system for diagnosis and grading of brain tumours using in vivo magnetic resonance single voxel spectra. NMR Biomed 2006 1.35
22 Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization. Mol Cancer Ther 2008 1.31
23 Aminopeptidase A is a functional target in angiogenic blood vessels. Cancer Cell 2004 1.28
24 Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial. Acta Neuropathol 2012 1.22
25 Prognostic value of estrogen receptor α and progesterone receptor conversion in distant breast cancer metastases. Cancer 2012 1.18
26 Robust detection of EGFR copy number changes and EGFR variant III: technical aspects and relevance for glioma diagnostics. Brain Pathol 2009 1.16
27 Keratitis caused by Scedosporium apiospermum successfully treated with a cornea transplant and voriconazole. J Clin Microbiol 2003 1.15
28 Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors. Neuro Oncol 2008 1.15
29 Magnetic resonance imaging-based detection of glial brain tumors in mice after antiangiogenic treatment. Int J Cancer 2008 1.14
30 IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. Acta Neuropathol 2015 1.13
31 Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951. Neuro Oncol 2009 1.13
32 Improved discrimination of melanotic schwannoma from melanocytic lesions by combined morphological and GNAQ mutational analysis. Acta Neuropathol 2010 1.11
33 IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas. Acta Neuropathol 2015 1.11
34 Primary intracranial germ-cell tumors in adults: a practical review. J Neurooncol 2013 1.10
35 Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. J Clin Oncol 2012 1.10
36 Multiplex ligation-dependent probe amplification: a diagnostic tool for simultaneous identification of different genetic markers in glial tumors. J Mol Diagn 2006 1.09
37 Monitoring of tumor growth and post-irradiation recurrence in a diffuse intrinsic pontine glioma mouse model. Brain Pathol 2010 1.09
38 Immunotherapy of diffuse gliomas: biological background, current status and future developments. Brain Pathol 2009 1.07
39 Collision sellar lesions: experience with eight cases and review of the literature. Pituitary 2009 1.05
40 Phenotypic and genotypic characterization of orthotopic human glioma models and its relevance for the study of anti-glioma therapy. Brain Pathol 2008 1.04
41 Effects of dual targeting of tumor cells and stroma in human glioblastoma xenografts with a tyrosine kinase inhibitor against c-MET and VEGFR2. PLoS One 2013 1.02
42 Differential effects of vascular endothelial growth factor A isoforms in a mouse brain metastasis model of human melanoma. Cancer Res 2003 1.02
43 Histological effects of fibrin glue on nervous tissue: a safety study in rats. Surg Neurol 2002 1.01
44 Citrullination of central nervous system proteins during the development of experimental autoimmune encephalomyelitis. J Comp Neurol 2005 1.01
45 Severe tacrolimus leukoencephalopathy after liver transplantation. AJNR Am J Neuroradiol 2003 1.00
46 Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT promoter methylation in gliomas: use with caution. Mod Pathol 2013 0.98
47 In vitro drug response and efflux transporters associated with drug resistance in pediatric high grade glioma and diffuse intrinsic pontine glioma. PLoS One 2013 0.98
48 Preparing pathology for personalized medicine: possibilities for improvement of the pre-analytical phase. Histopathology 2011 0.97
49 MGMT-STP27 methylation status as predictive marker for response to PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951. Clin Cancer Res 2013 0.97
50 Comparison between neuroimaging classifications and histopathological diagnoses using an international multicenter brain tumor magnetic resonance imaging database. J Neurosurg 2006 0.96
51 EFEMP1 induces γ-secretase/Notch-mediated temozolomide resistance in glioblastoma. Oncotarget 2014 0.96
52 Subventricular spread of diffuse intrinsic pontine glioma. Acta Neuropathol 2014 0.95
53 Myc-associated zinc finger protein (MAZ) is regulated by miR-125b and mediates VEGF-induced angiogenesis in glioblastoma. FASEB J 2012 0.95
54 Accumulation of heparan sulfate proteoglycans in cerebellar senile plaques. Neurobiol Aging 2002 0.94
55 Comparative genomic hybridization: practical guidelines. Diagn Mol Pathol 2002 0.94
56 Vascular endothelial growth factor-A determines detectability of experimental melanoma brain metastasis in GD-DTPA-enhanced MRI. Int J Cancer 2003 0.93
57 Protein tyrosine phosphatases in glioma biology. Acta Neuropathol 2009 0.92
58 Human pontine glioma cells can induce murine tumors. Acta Neuropathol 2014 0.92
59 MAPK pathway activation through BRAF gene fusion in pilocytic astrocytomas; a novel oncogenic fusion gene with diagnostic, prognostic, and therapeutic potential. J Pathol 2010 0.92
60 Molecular pathogenesis of oligodendroglial tumors. J Neurooncol 2004 0.91
61 Increased mitochondrial activity in a novel IDH1-R132H mutant human oligodendroglioma xenograft model: in situ detection of 2-HG and α-KG. Acta Neuropathol Commun 2013 0.91
62 Effects of targeting the VEGF and PDGF pathways in diffuse orthotopic glioma models. J Pathol 2011 0.90
63 Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment. Acta Neuropathol 2015 0.90
64 Experimental treatment of NRAS-mutated neurocutaneous melanocytosis with MEK162, a MEK-inhibitor. Acta Neuropathol Commun 2014 0.90
65 Accurate classification of childhood brain tumours by in vivo ¹H MRS - a multi-centre study. Eur J Cancer 2012 0.89
66 Spatial and temporal evolution of distal 10q deletion, a prognostically unfavorable event in diffuse low-grade gliomas. Genome Biol 2014 0.89
67 A pilot study on slit lamp-adapted optical coherence tomography imaging of trabeculectomy filtering blebs. Graefes Arch Clin Exp Ophthalmol 2006 0.88
68 Correlation between localization, age, and chromosomal imbalances in ependymal tumours as detected by CGH. J Pathol 2002 0.87
69 Mutations in g protein encoding genes and chromosomal alterations in primary leptomeningeal melanocytic neoplasms. Pathol Oncol Res 2014 0.87
70 Expression pattern of apoptosis-related markers in Huntington's disease. Acta Neuropathol 2005 0.86
71 Pheochromocytoma and gastrointestinal stromal tumors in patients with neurofibromatosis type I. Am J Med 2013 0.85
72 Chromosomal imbalances in primary oligodendroglial tumors and their recurrences: clues about malignant progression detected using comparative genomic hybridization. J Neurosurg 2002 0.85
73 Development of the tumor vascular bed in response to hypoxia-induced VEGF-A differs from that in tumors with constitutive VEGF-A expression. Int J Cancer 2006 0.85
74 Multivoxel ¹H MR spectroscopy is superior to contrast-enhanced MRI for response assessment after anti-angiogenic treatment of orthotopic human glioma xenografts and provides handles for metabolic targeting. Neuro Oncol 2013 0.85
75 Collagen XVIII: a novel heparan sulfate proteoglycan associated with vascular amyloid depositions and senile plaques in Alzheimer's disease brains. Brain Pathol 2002 0.84
76 Three-dimensional (3D) reconstruction and quantitative analysis of the microvasculature in medulloblastoma and ependymoma subtypes. Angiogenesis 2006 0.83
77 Increase in both CD14-positive and CD15-positive myeloid-derived suppressor cell subpopulations in the blood of patients with glioma but predominance of CD15-positive myeloid-derived suppressor cells in glioma tissue. J Neuropathol Exp Neurol 2015 0.83
78 A novel seven-octapeptide repeat insertion in the prion protein gene (PRNP) in a Dutch pedigree with Gerstmann-Sträussler-Scheinker disease phenotype: comparison with similar cases from the literature. Acta Neuropathol 2010 0.83
79 Whole-genome copy-number analysis identifies new leads for chromosomal aberrations involved in the oncogenesis and metastastic behavior of uveal melanomas. Melanoma Res 2015 0.82
80 Cyclin D1 genotype and expression in sporadic hemangioblastomas. J Neurooncol 2005 0.82
81 The nature and timing of specific copy number changes in the course of molecular progression in diffuse gliomas: further elucidation of their genetic "life story". Brain Pathol 2010 0.82
82 3'-Deoxy-3'-18F-fluorothymidine PET-derived proliferative volume predicts overall survival in high-grade glioma patients. J Nucl Med 2012 0.82
83 Liquid biopsies in patients with diffuse glioma. Acta Neuropathol 2015 0.82
84 Identification of a novel MET mutation in high-grade glioma resulting in an auto-active intracellular protein. Acta Neuropathol 2015 0.82
85 Clinical value of chromosome arms 19q and 11p losses in low-grade gliomas. Neuro Oncol 2013 0.81
86 Alpha-internexin expression predicts outcome in anaplastic oligodendroglial tumors and may positively impact the efficacy of chemotherapy: European organization for research and treatment of cancer trial 26951. Cancer 2011 0.81
87 Correlation between contrast enhancement on intraoperative magnetic resonance imaging and histopathology in glioblastoma. Surg Neurol Int 2012 0.81
88 Analysis of von hippel-lindau mutations with comparative genomic hybridization in sporadic and hereditary hemangioblastomas: possible genetic heterogeneity. J Neurosurg 2002 0.81
89 White Matter Lesions Are Not Related to β-Amyloid Deposition in an Autopsy-Based Study. Curr Gerontol Geriatr Res 2011 0.81
90 Unique Presentation of Corneal Opacity in Peters Plus Syndrome: An Unusual Form of Peters Anomaly Showing Tissue Repair in Serial Analysis. Cornea 2016 0.80
91 Upregulation of Claudin-4, CAIX and GLUT-1 in distant breast cancer metastases. BMC Cancer 2014 0.80
92 Gliomatosis cerebri: quantitative proof of vessel recruitment by cooptation instead of angiogenesis. J Neurosurg 2005 0.80
93 SMARCB1 involvement in the development of leiomyoma in a patient with schwannomatosis. Am J Surg Pathol 2014 0.80
94 Letter in response to David N. Louis et al, International Society of Neuropathology-Haarlem Consensus Guidelines for Nervous System Tumor Classification and Grading, Brain Pathology, doi: 10.1111/bpa.12171. Brain Pathol 2014 0.79
95 Cerebral amyloid angiopathy with severe secondary vascular pathology: a histopathological study. Dement Geriatr Cogn Disord 2005 0.79
96 Premature termination of SMARCB1 translation may be followed by reinitiation in schwannomatosis-associated schwannomas, but results in absence of SMARCB1 expression in rhabdoid tumors. Acta Neuropathol 2014 0.79
97 Molecular diagnostics as a tool to personalize treatment in adult glioma patients. Technol Cancer Res Treat 2006 0.79
98 Radiotherapy for partially resected spinal ependymomas: a retrospective study of 60 cases. Oncol Rep 2003 0.79
99 Primary melanocytic tumors of the central nervous system: a review with focus on molecular aspects. Brain Pathol 2015 0.79
100 Accurate Delineation of Glioma Infiltration by Advanced PET/MR Neuro-Imaging (FRONTIER Study): A Diagnostic Study Protocol. Neurosurgery 2016 0.78
101 Re: multiplex ligation dependent probe amplification for the detection of 1p and 19q loss in oligodendroglial tumors. Brain Pathol 2005 0.78
102 Selective cancer-germline gene expression in pediatric brain tumors. J Neurooncol 2008 0.78
103 Compatibility between 3T 1H SV-MRS data and automatic brain tumour diagnosis support systems based on databases of 1.5T 1H SV-MRS spectra. MAGMA 2011 0.77
104 Incremental Gaussian Discriminant Analysis based on Graybill and Deal weighted combination of estimators for brain tumour diagnosis. J Biomed Inform 2011 0.76
105 Molecular diagnostics of brain tumors. Acta Neuropathol 2010 0.76
106 Multiplex blood reporters for simultaneous monitoring of cellular processes. Anal Chem 2013 0.75
107 [Neuroschistosomiasis; an unexpected finding in a Dutch woman]. Ned Tijdschr Geneeskd 2009 0.75
108 Fatal consequences of an ear infection. Lancet 2009 0.75
109 Towards an integrated morphological and molecular WHO diagnosis of central nervous system tumors: a paradigm shift. Curr Opin Neurol 2015 0.75
110 [Constitutional mismatch repair deficiency syndrome]. Ned Tijdschr Geneeskd 2015 0.75
111 Absence of heparan sulfate proteoglycans in Lewy bodies and Lewy neurites in Parkinson's disease brains. J Alzheimers Dis 2004 0.75
112 Six year survival after prolonged temozolomide treatment in a 30-year-old patient with glioblastoma. Acta Neurol Belg 2009 0.75
113 Fatal thrombotic microangiopathy after a single dose of gemcitabine as fourth-line palliative treatment for metastasized ductal breast carcinoma. Acta Oncol 2010 0.75
114 A clinicopathologic study of 11 rosette-forming meningiomas: a rare and potentially confusing pattern. Acta Neuropathol 2015 0.75
115 Occurrence of ocular melanoma thirteen years after skin melanoma: two separate primaries or metastatic disease? A case solved with NRAS and CDKN2A (INK4A-ARF) mutational analysis. Virchows Arch 2008 0.75
116 Molecular analysis as a tool in the differential diagnosis of VHL disease-related tumors. Diagn Mol Pathol 2005 0.75